代谢功能障碍相关脂肪性肝病与脂肪性肝炎的实用管理策略
本文提出一种基于风险的实用且易实施的MASLD评估与管理方法,强调治疗目标是改善代谢炎症状态、预防纤维化进展至肝硬化,并对已肝硬化者预防门静脉高压相关结局,纤维化逆转是关键目标。
要点
- MASLD/MASH治疗应针对代谢炎症这一根源,以纤维化逆转为核心目标。
- 已进展至肝硬化者需额外管理以预防门静脉高压相关结局。
- MASLD患者常合并多种代谢共病,需整体评估风险并整合管理。
核心结论
- 本文提供一种基于风险的实用且易实施的MASLD评估与管理方法,强调治疗应改善代谢炎症状态并预防纤维化进展。
研究设计与样本
- 本文为实用管理策略综述,未报告系统检索范围与样本量。
主要发现
- 肥胖及相关胰岛素抵抗诱导慢性代谢炎症状态,导致2型糖尿病、高血压、心血管疾病、慢性肾脏病和MASLD等多种非传染性疾病。
- MASH是MASLD的组织学活动形式,以更严重的损伤和炎症为特征,比单纯脂肪变性更确定地进展为肝硬化。
- 进展至肝硬化的特征为纤维化增加,纤维化逆转是治疗的关键目标。
- 近期resmetirom获批用于伴纤维化的MASH,以及胰高血糖素样肽-1受体激动剂用于肥胖和2型糖尿病,增加了对肥胖个体肝脏评估和护理的需求。
临床怎么用
- 对MASLD患者应评估全部风险并采取整体方法整合管理所有生命威胁。
- 治疗目标为改善代谢炎症状态以预防纤维化进展至肝硬化,已肝硬化者需额外护理以预防门静脉高压相关结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity and associated insulin resistance induce a chronic metaboinflammatory state that lead to injury and dysfunction of multiple organs resulting in a cluster of noncommunicable diseases such as type 2 diabetes mellitus, hypertension, cardiovascular disease, chronic kidney disease, and metabolic dysfunction-associated steatotic liver disease (MASLD). Metabolic dysfunction-associated steatohepatitis (MASH) is a histologically active form of MASLD and characterized by greater injury and inflammation and progresses to cirrhosis with greater certainty than steatosis alone. The progression to cirrhosis is characterized by increasing fibrosis. The goal of treatment of MASLD/MASH was to improve the metaboinflammatory state i.e., the root cause of the liver disease and to prevent fibrosis progression to cirrhosis whereas in those who already have cirrhosis need additional care to prevent portal hypertension-related outcomes. Fibrosis regression is thus a key objective of treatment. The recent approval of resmetirom for MASH with fibrosis and the use of glucagon-like peptide-1 receptor agonists for obesity and type 2 diabetes has increased awareness of these NCDs and resulted in the growing demand for liver assessment and care in obese individuals. Patients with MASLD also have multiple metabolic comorbidities which represent competing threats to life, and the care of the patient requires both assessment of the totality of the risk and a more holistic approach integrating the care of all of the threats to life. Here, we provide a pragmatic and easily implementable risk-based approach to the evaluation and management of MASLD.
引用
- Shah N, Sanyal AJ. A Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis. Am J Gastroenterol. 2024. PMID: 39569874. doi:10.14309/ajg.0000000000003215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。